MiNK Therapeutics Inc. (NASDAQ: INKT) announced the initiation of a Phase 1 clinical trial evaluating its experimental cell therapy agenT-797 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE